Skip to main content
$13.70 -$0.02 (-0.1%)

10:51 AM EDT on 10/27/21

G1 Therapeutics (NASDAQ:GTHX)

CAPS Rating: 5 out of 5

Current Price $13.70 Mkt Cap $581.0M
Open $13.74 P/E Ratio 0.00
Prev. Close $13.72 Div. (Yield) $0.00 (0.0%)
Daily Range $13.46 - $13.80 Volume 235,366
52-Wk Range $10.81 - $37.07 Avg. Daily Vol. 907,196

Caps

How do you think NASDAQ:GTHX will perform against the market?

Add Stock to CAPS Watchlist

All Players

19 Outperform
0 Underperform
 

All-Star Players

3 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:GTHX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mdriver78 (75.44)
Submitted December 16, 2020

The company, G1 Therapeutics (NASDAQ: GTHX) sits in a sweet spot valuation-wise — cancer biotech companies with valuations between $500 million and $1 billion often are the best performers going into an FDA decision.That valuation is big enough to… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:GTHX VS S&P 500 (SPY)

NASDAQ:GTHX Summary

Fools bullish on NASDAQ:GTHX are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about GTHX.

Recs

2
Member Avatar mdriver78 (75.44) Submitted: 12/16/2020 11:35:41 AM : Outperform Start Price: $19.55 NASDAQ:GTHX Score: -52.82

The company, G1 Therapeutics (NASDAQ: GTHX) sits in a sweet spot valuation-wise — cancer biotech companies with valuations between $500 million and $1 billion often are the best performers going into an FDA decision.

That valuation is big enough to suggest a good likelihood of an FDA approval, while still being small enough to produce big gains should it occur.

The company’s drug, trilaciclib, is designed to protect bone marrow cells from being ravaged by chemotherapy drugs. It has been tested in patients receiving chemo drugs for lung cancer. The company recently reported significant improvement in overall survival for patients using the drug. And data have been strong enough to prompt G1 to file an FDA application.

Trilaciclib is also in clinical trials for patients with breast and colorectal cancers. Moreover, G1 has two other compounds in four additional cancer trials.

Sounding the alarm as it detects a spike in activity as insiders position themselves ahead of the company’s FDA approval date — set for Feb. 15, 2021.

Insiders are often in the best position to judge the prospects for a new drug before an FDA event, and a spike like this one suggests that sentiment has turned very bullish.

Moreover, this unusual activity hasn’t just been high for a session or two. It has been high all month!

Recs

1
Member Avatar TMFSpiffyPop (99.90) Submitted: 7/28/2017 2:45:03 PM : Outperform Start Price: $14.59 NASDAQ:GTHX Score: -90.56

Picking mainly just to remind myself to research further. Outperform.

Leaderboard

Find the members with the highest scoring picks in GTHX.

Score Leader

NFender

NFender (99.92) Score: +160.15

The Score Leader is the player with the highest score across all their picks in GTHX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
stereotyp72 76.47 11/23/2020 Outperform 5Y $12.65 +8.70% +27.65% -18.95 0 Comment
Gmoney70 50.52 7/23/2021 Outperform 5Y $18.48 -25.60% +4.22% -29.81 0 Comment
losj < 20 3/25/2021 Outperform 5Y $19.86 -30.77% +17.83% -48.60 0 Comment
mdriver78 75.44 12/16/2020 Outperform 5Y $19.55 -29.67% +23.15% -52.82 2 Comments
kfassini < 20 2/26/2021 Outperform 5Y $21.89 -37.19% +19.69% -56.87 0 Comment
fm4alpha 35.43 3/12/2020 Outperform 3M $12.26 +12.15% +80.27% -68.11 0 Comment
bonjourmesamis 72.81 2/4/2021 Outperform 5Y $28.12 -51.10% +19.06% -70.17 0 Comment
Quills19 < 20 2/11/2021 Outperform 1Y $30.79 -55.34% +16.59% -71.93 0 Comment
Nafi < 20 2/12/2021 Outperform 5Y $30.80 -55.36% +16.96% -72.32 0 Comment
avtk45a < 20 12/9/2019 Outperform 5Y $20.73 -33.67% +45.16% -78.83 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GTHX.